New combo aims to tackle Hard-to-Treat myeloma

NCT ID NCT06988488

Recruiting now Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two drugs, mezigdomide and elranatamab, together in people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 62 adults will take part in this early-stage trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mezigdomide and elranatamab (with dexamethasone)
What this could lead to: If successful, this combination could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 62 participants, so results may not apply to everyone. The drugs may cause serious side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Alexandra General Hospital of Athens
RECRUITING

Athens, Attikí, 115 28, Greece
Arthur J E Child Comprehensive Cancer Centre
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Evangelismos General Hospital of Athens
RECRUITING

Athens, Attikí, 106 76, Greece
Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Hospital Universitario Marqués de Valdecilla
RECRUITING

Santander, Cantabria, 39008, Spain
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
RECRUITING

Salamanca, 37007, Spain
Local Institution - 0026
NOT_YET_RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
Local Institution - 0030
NOT_YET_RECRUITING

Suzhou, Jiangsu, 215006, China
Local Institution - 0031
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200434, China
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
QEII Health Sciences Centre - Victoria General Site
RECRUITING

Halifax, Nova Scotia, B3H 2Y9, Canada
Royal Marsden Hospital (Sutton)
RECRUITING

London, Sutton, SM2 5PT, United Kingdom
St. Olavs Hospital
RECRUITING

Trondheim, Sør-Trøndelag, 7030, Norway
Sykehusapoteket Ull
RECRUITING

Oslo, 0450, Norway
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
Universitaetsklinikum Carl Gustav Carus Dresden
RECRUITING

Dresden, 01307, Germany
Universitaetsklinikum Hamburg-Eppendorf
RECRUITING

Hamburg, 20246, Germany
Universitaetsklinikum Heidelberg
RECRUITING

Heidelberg, 69120, Germany
University College London Hospital
RECRUITING

London, England, W1T 7HA, United Kingdom
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Yale New Haven Hospital-Smilow Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.